Merck’s Erbitux backed by NICE for head and neck cancer
Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck.
Read More
Tag: SCCHN
FDA clears Opdivo for head and neck cancer
Bristol-Myers Squibb’s Opdivo has become the first immuno-oncology therapy to win US Food and Drug Administration approval for head and neck cancer.
Read More
BMS’ Opdivo continues to impress at ESMO
Bristol Myers Squibb’s immunotherapy Opdivo not only extends survival in patients with a certain type of head and neck cancer but data, presented at the European Society of Medical Oncology congress, also show improvements on quality of life measures.
Read More
BMS’ Opdivo gets US, EU reviews for head and neck cancer
Regulators on both sides of the Atlantic have agreed to review Bristol-Myers Squibb’s immunotherapy Opdivo for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
